CPSE:BAVABiotechs
A Look At Bavarian Nordic (CPSE:BAVA) Valuation After New US$97 Million Vaccine Contract And Guidance Upgrade
Bavarian Nordic (CPSE:BAVA) is back in focus after securing US$97 million in contract options from the U.S. government for freeze dried smallpox vaccines and lifting its full year 2026 financial guidance.
See our latest analysis for Bavarian Nordic.
At a share price of DKK194.6, Bavarian Nordic has seen a 1-year total shareholder return of 16.84%, while the 5-year total shareholder return is down 28.27%. This suggests that recent momentum has improved compared with a weaker longer term...